MARKET

CCXI

CCXI

ChemoCentryx
NASDAQ

Real-time Quotes | Nasdaq Last Sale

41.27
+0.53
+1.30%
After Hours: 41.27 0 0.00% 16:41 01/24 EST
OPEN
41.47
PREV CLOSE
40.74
HIGH
43.08
LOW
40.35
VOLUME
576.84K
TURNOVER
--
52 WEEK HIGH
44.21
52 WEEK LOW
6.16
MARKET CAP
2.40B
P/E (TTM)
-44.6887
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of CCXI and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 6 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

CCXI News

  • 10 Biggest Price Target Changes For Friday
  • Benzinga.1d ago
  • H.C. Wainwright Maintains Buy on ChemoCentryx, Raises Price Target to $60
  • Benzinga.2d ago
  • The Daily Biotech Pulse: Johnson & Johnson Earnings, FDA Nod For Horizon Therapeutics, Slew Of Secondary Offerings
  • Benzinga.3d ago
  • The Daily Biotech Pulse: Novo Nordisk's Ozempic Receives Label Expansion For Cardiovascular Events, Adcom Disappointment Inflicts Pain On Durect Shares
  • Benzinga.01/17 13:07

More

Industry

Pharmaceuticals
-1.84%
Pharmaceuticals & Medical Research
-2.00%

Hot Stocks

Name
Price
%Change

About CCXI

ChemoCentryx, Inc. is a biopharmaceutical company. The Company is engaged in developing new medications targeted at inflammatory disorders, autoimmune diseases and cancer. Each of its drug candidates focuses on a specific chemoattractant receptor that selectively blocks its negative inflammatory or suppressive response, leaving the rest of the immune system intact. Its late stage compounds include Avacopan (CCX168) and CCX140. Avacopan (CCX168) is an orally administered complement inhibitor targeting the C5a receptor (C5aR), and is being developed for orphan and rare diseases, including anti-neutrophil cytoplasmic auto-antibody associated vasculitis (AAV); atypical hemolytic uremic syndrome (aHUS), and complement 3 glomerulopathy (C3G). CCX140 is an orally administered inhibitor of the chemokine receptor known as C-C chemokine receptor type 2 (CCR2), in development for diabetic nephropathy (DN), a form of chronic kidney disease (CKD), and for focal segmental glomerulosclerosis (FSGS).
More

Webull offers ChemoCentryx Inc (CCXI) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.